ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2011
Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.
Article in Annals of oncology : official journal of the European Society for Medical Oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 1,787 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Tailored Neoadjuvant Epirubicin and Cyclophosphamide (EC) and Nanoparticle Albumin Bound (Nab) Paclitaxel for Newly Diagnosed Breast Cancer
Evaluation of Medical Treatments (Chemotherapy, Hormonal Therapy and Biological Therapies) in Metastatic Breast Cancer Patients According to Biologic Subtype and Line of Treatment
Early Assessment of Shear Wave Elastography Parameters to Assess the Response to Neoadjuvant Chemotherapy in Patients With Invasive Breast Cancer
GISEL (Italian Senologic Group for Electrochemotherapy): Prospective Multicenter Registry of Breast Cancer Patients With Skin Metastases Treated by Electrochemotherapy
Who cites it
1,787 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Ferroptosis in chemotherapy resistance and resensitization in breast cancer: a systematic review of preclinical evidence and translational implications.Frontiers in oncology · 2026Pooled it
- Safety and efficacy of docosahexaenoic acid supplementation during neoadjuvant breast cancer therapy: Findings from the phase II, double-blind, randomized controlled DHA-WIN trial.International journal of cancer · 2025Trial
- Article
- Role of tumor necrosis factor receptor superfamily member 19 in cancer: Diverse functions and therapeutic potential (Review).Oncology letters · 2026Review
- Automated mRNA-Based Detection of ER, PR, HER2, and Ki-67 in Breast Cancer Tissue and Cytology Samples in Resource-Limited Settings.Cancer medicine · 2026Article
- AMCP Market Insights: Managed care approaches toJournal of managed care & specialty pharmacy · 2026Article
- Association Between Sleep Disorders and Breast Cancer: An Analysis Based on NHANES and Mendelian Randomization.World journal of oncology · 2026Article
- Article
- Effects of short-course preoperative endocrine therapy on tumour morphology and immunohistochemical profile in oestrogen receptor-positive, HER2-negative breast cancer.Histopathology · 2026Article
- Moran's index habitat and peritumoral radiomics based on digital breast tomosynthesis for predicting Ki-67 status in breast cancer.Quantitative imaging in medicine and surgery · 2026Article
- Subtype-specific screen-detected and interval breast cancer rates in population screening: a BreastScreen Queensland cohort study.Breast (Edinburgh, Scotland) · 2026Article
- Concordance of Digital Breast Tomosynthesis (DBT) and Magnetic Resonance Imaging (MRI) Measured Tumor Size with the Pathological Gold Standard: A Retrospective Cohort Analysis by Molecular Subtype and Breast Density.Diagnostics (Basel, Switzerland) · 2026Article
- AI-Assisted Scoring Improves Interobserver Agreement in Breast Cancer Biomarker Evaluation.Cancers · 2026Article
- Deep learning radiomics based on preoperative multiparametric MRI in predicting breast cancer recurrence risk.BMC medical imaging · 2026Article
- Dysregulation of the TLR4/MYD88 Signaling Pathway in Egyptian Females with Breast Cancer: Implications for Tumor Progression.Molecular biology reports · 2026Article
- Amide proton transfer-weighted magnetic resonance imaging for the diagnosis of triple-negative breast cancer: a comparative study with diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging.Quantitative imaging in medicine and surgery · 2026Article
- Breast Cancer in Women Aged ≤35 Years: A Single-Center Retrospective Comparative Analysis by Age Subgroup.Diagnostics (Basel, Switzerland) · 2026Article
- A Parsimonious Ultrasound Radiomics and Ki-67 Model for Estimating MammaPrint Risk Categorization in HR+/HER2- Early Breast Cancer.Current oncology (Toronto, Ont.) · 2026Article
- HER2-directed therapy is associated with an increased rate of cardiologic emergency department visits in real-world breast cancer patients.Breast (Edinburgh, Scotland) · 2026Article
- Axillary Pathologic Complete Response as a Stronger Prognostic Marker than Breast pCR in Clinically Node-Positive Stage II-III Breast Cancer.Annals of surgical oncology · 2026Article
1,727 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The 12th St Gallen International Breast Cancer Conference (2011) Expert Panel adopted a new approach to the classification of patients for therapeutic purposes based on the recognition of intrinsic biological subtypes within the breast cancer spectrum. For practical purposes, these subtypes may be approximated using clinicopathological rather than gene expression array criteria. In general, systemic therapy recommendations follow the subtype classification. Thus, 'Luminal A' disease generally requires only endocrine therapy, which also forms part of the treatment of the 'Luminal B' subtype. Chemotherapy is considered indicated for most patients with 'Luminal B', 'Human Epidermal growth factor Receptor 2 (HER2) positive', and 'Triple negative (ductal)' disease, with the addition of trastuzumab in 'HER2 positive' disease. Progress was also noted in defining better tolerated local therapies in selected cases without loss of efficacy, such as accelerated radiation therapy and the omission of axillary dissection under defined circumstances. Broad treatment recommendations are presented, recognizing that detailed treatment decisions need to consider disease extent, host factors, patient preferences, and social and economic constraints.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.